-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DyhCv/9knC1z0LrUvWj17yBTXyDWyWpZB4qGJdJBDyAtwHEC7an+qZsHqTtoS0+S mgvjO9qzY0AeJxeffg86Uw== 0001104659-10-053110.txt : 20101021 0001104659-10-053110.hdr.sgml : 20101021 20101021134249 ACCESSION NUMBER: 0001104659-10-053110 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20101018 ITEM INFORMATION: Other Events FILED AS OF DATE: 20101021 DATE AS OF CHANGE: 20101021 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MESA LABORATORIES INC /CO CENTRAL INDEX KEY: 0000724004 STANDARD INDUSTRIAL CLASSIFICATION: INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL [3823] IRS NUMBER: 840872291 STATE OF INCORPORATION: CO FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-11740 FILM NUMBER: 101134759 BUSINESS ADDRESS: STREET 1: 12100 W 6TH AVE CITY: LAKEWOOD STATE: CO ZIP: 80228 BUSINESS PHONE: 3039878000 MAIL ADDRESS: STREET 1: 12100 W 6TH AVE CITY: LAKEWOOD STATE: CO ZIP: 80228 FORMER COMPANY: FORMER CONFORMED NAME: MESA MEDICAL INC DATE OF NAME CHANGE: 19921123 8-K 1 a10-19764_18k.htm 8-K

 

 

U.S. Securities and Exchange Commission

Washington, D.C. 20549

 

Form 8-K

 

Current Report

 

Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

 

OCTOBER 18, 2010

Date of Report (Date of earliest event Reported)

 

MESA LABORATORIES, INC.

(Exact Name of Small Business Issuer as Specified in its Charter)

 

Commission File Number: 0-11740

 

COLORADO
(State or other Jurisdiction of
Incorporation or Organization)

 

84-0872291
(I.R.S. Employer
Identification No.)

 

12100 WEST SIXTH AVENUE, LAKEWOOD,
COLORADO
(Address of Principal Executive Offices)

 

80228
(Zip Code)

 

Issuer’s telephone number, including area code: (303) 987-8000

 

Not Applicable.

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

ITEM 8.01   OTHER EVENTS.

 

Mesa Laboratories, Inc., on July 21, 2010, received a letter from Nasdaq informing the Company that due to the resignation of Mr. Paul D. Duke from its Board of Directors effective as of July 7, 2010, the Company no longer complied with Nasdaq’s independent director requirements as set forth in Listing Rule 5605.   Per Nasdaq Listing Rule 5605(b)(1), the company was provided a cure period that was to last until January 3, 2011, to provide evidence of compliance. Based on the information regarding the appointment of David M. Kelly to the Company’s Board of Directors, as detailed in our Form 8-K dated October 12, 2010, NASDAQ has determined that the Company complies with the Rule and this matter is now closed.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

MESA LABORATORIES, INC.

 

(Issuer)

 

 

 

 

 

DATED: October 18, 2010

BY:

/s/ John J. Sullivan

 

 

 

 

 

John J. Sullivan, Ph.D.
Chief Executive Officer,
President, Treasurer and
Director

 

2

 -----END PRIVACY-ENHANCED MESSAGE-----